1

DATE PREPARED: 14 May 2015 Name: Ronald C. Chen, MD MPH Office Address: Department of Radiation Oncology, University of North Carolina, Campus Box

7512, Chapel Hill, NC 27599 Education: 1999 B.A. University of Kansas, Lawrence, KS 2004 M.D. Harvard Medical School, Boston, MA 2008 MPH Harvard School of Public Health, Boston, MA Postdoctoral Training: July ’04 – July ’05 Intern in Internal Medicine, Massachusetts General Hospital, Boston, MA

July ’05 – June ’09 Resident in Radiation Oncology, Harvard Radiation Oncology Program, Boston, MA

July ’08 – June ’09 Chief resident, Harvard Radiation Oncology Program, Boston, MA Licensure and Certification:

2006 Commonwealth of Massachusetts License 2009 North Carolina License 6-30-2010 Board certification in Radiation Oncology (ABR) 2015 American Board of Radiology Focused Practice Recognition in Brachytherapy

Academic Appointments:

2009-2014 Assistant Professor, Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC

2009-present Fellow, Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC 2009-present Member, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 2014-present Associate Director, UNC Cyberknife Program 2014-2015 Assistant Director, Residency Program 2014-present Clinical Assistant Professor, Department of Urology, UNC 2014-present Associate Professor with Tenure, Department of Radiation Oncology 2015-present Program Director, Residency Program

Major Committee Assignments: International: Movember TrueNTH International Collaborative Network: Global Evaluation and Health Economics team member National: American Society for Radiation Oncology (ASTRO) 2010-2013 Member, Health Services Research Committee of the Research Council

Vice chair of committee: 2011-2012

Chair: 2012-2013 2011-2013 Chair, Radiation Treatment Summary Template Project, ASTRO 2011-present Member, Measures Subcommittee of the Clinical Affairs and Quality Committee 2012-2014 Member, National Radiation Oncology Registry (NROR) Pilot Committee 2012-present Scientific abstract reviewer, ASTRO Annual Meeting 2013-2015 Track chair [Patient Reported Outcomes], ASTRO Annual Meeting 2013-present Member, ASTRO Annual Meeting Scientific Committee

2

2013-present Member, ASTRO Science Council Executive Committee 2013-2014 Chair, ASTRO Clinical, Translational and Basic Science Advisory Committee

(2014-2015, Immediate Past Chair) American Society of Clinical Oncology (ASCO) 2012-present Member, Clinical Practice Guidelines Committee (2014-present, member of

Methodology Subcommittee) 2013-present Member, Survivorship Care Plan Working Group 2014 Member, Expert panel to develop a guideline endorsement on “Adjuvant and

salvage radiotherapy after prostatectomy: AUA/ASTRO guideline” 2015-present Co-chair, Expert panel to endorse a guideline for active surveillance in localized

prostate cancer 2015-present Member, Quality of Care Committee 2015-present Member, ASCO Annual Meeting Scientific Program Committee Clinical Trials Cooperative Groups 2011-2014 Member, Comparative Effectiveness and CCOP Committees, Radiation Therapy

Oncology Group (RTOG)

Co-PI of RTOG 1218: hypofractionated radiation for prostate cancer\ 2014-present Member, Cancer Prevention and Control (CPC) and GU Committees, NRG

Oncology

PI of developing trial for node-positive prostate cancer

Liaison CPC liaison to GU committee 2011-present Member, Health Outcomes, GU and Cancer Care Delivery committees, the

Alliance for Clinical Trials in Oncology

Vice Chair of GU committee (for outcomes) Other National Committees 2011-2014 Member, NCI Committee on Identification of Core Symptom and Health-Related

Quality of Life Domains for use in Cancer Research

First/corresponding author of white paper describing NCI recommendations for prostate cancer trials

2012-present Member, American Association of Physicists in Medicine (AAPM) Working Group on Biologic Effects of Hypofractionated Radiotherapy/SBRT

Co-chair of pelvic subcommittee 2013-present Chartrounds.com: GU specialist 2013 Patient-Centered Research Outcomes Institute (PCORI) Patient Reported

Outcomes Infrastructure Workshop. Invited attendee. November 19-20, 2013. 2014-present American Urological Society (AUA) Localized Prostate Cancer panel 2015-present Patient-Centered Research Outcomes Institute (PCORI) Advisory Panel on

Clinical Trials (CTAP) Post-Award Expert Advisory Subcommittee University of North Carolina: 2009-present Member, Residency Executive Committee, Department of Radiation Oncology

2013-present: Chair, Clinical Competency Committee 2009-2015 Member, Lineberger Cancer Center Protocol Review Committee

2012-2015: Member, Executive Sub-Committee 2009-2014 Member, Lineberger Cancer Center, Lance Armstrong Foundation Survivorship

Program Leadership Team 2009-2014 Advisory Board, Carolina Well (Lineberger Cancer Center Survivorship Program) 2010-2013 Elected member, University of North Carolina Faculty Council. 2010-2012 Liaison Committee on Medical Education (LCME), University of North Carolina

Self-Study Committee 2011-present Member, Data Safety Monitoring Board 2014-present Member, TraCS Interdisciplinary Advisory Committee

3

2012-2014 Director, Cyberknife program 2014-present Associate Director, Cyberknife program 2014-present Assistant Director, residency program 2014-present Member, Lineberger Comprehensive Cancer Center Survivorship Advisory Board 2015-present Carolina Value, School of Medicine Finance and Operations Implementation

Team Previous Committees:

2002-2003 Member, Harvard Medical School Division of Health Sciences and Technology Admissions Committee

2007, 2009 Member, Harvard Radiation Oncology Program Residency Candidate Selection Committee

2007-2009 Member, Harvard Medical School Division of Health Sciences and Technology Board of Advisors

2005-2007 Member, Massachusetts General Hospital Executive Committee on Education and Teaching

2006-2009 Member, Brigham and Women’s Hospital Ethics Committee 2007-2009 Member, Frontier Science Institutional Review Board 2007-2008 Member, Dana-Farber Cancer Institute/Brigham and Women’s Hospital

Department of Radiation Oncology ARIA Implementation Team 2008-2009 Member, Brigham and Women’s Hospital Ethics Steering Committee 2008-2009 Member, Massachusetts General Hospital Department of Radiation Oncology

Quality Assurance (QA) Committee 2008-2009 Member, Massachusetts General Hospital Department of Radiation Oncology

Lean Process Improvement Committee Leadership Development: 2014 ASTRO Disciplines of Leadership Course attendee 2014-15 Selected participant of ASCO Leadership Development Program 2015 Selected participant of University of North Carolina Faculty Leadership Initiative

Course Professional Societies: 2006-present Member, American Society of Clinical Oncology 2006-present Member, American Society of Radiation Oncology Journal Editorship: 2013 Guest editor, Comparative Effectiveness Research in Oncology issue, Seminars

in Radiation Oncology 2014-2016 Editorial Board, Journal of Clinical Oncology 2014-present Editorial Board, Frontiers in Radiation Oncology 2014-present Editorial Board, Urologic Oncology 2014-present Senior Editor, Practical Radiation Oncology Journal Reviews: 2009-2014 Gynecologic Oncology, ad hoc reviewer 2009-present Cancer, ad hoc reviewer 2010-present Urology, ad hoc reviewer 2010-present Journal of Medical Imaging and Radiation Sciences, ad hoc reviewer 2010-present International Journal of Radiation Oncology, Biology & Physics, ad hoc reviewer

[2013: certificate of excellence in reviewing] 2011-present Radiotherapy and Oncology, ad hoc reviewer 2011-present BJU International, ad hoc reviewer

4

2011-present Asian Journal of Andrology, ad hoc reviewer 2012-present Quality of Life Research, ad hoc reviewer 2012-present Practical Radiation Oncology, ad hoc reviewer [2013: certificate of excellence in

reviewing] 2012-present Urologic Oncology: Seminars and Original Investigations, ad hoc reviewer 2012-present The Oncologist, ad hoc reviewer 2012-present Journal of Clinical Oncology, ad hoc reviewer 2012-present JAMA Internal Medicine, ad hoc reviewer 2012-present Radiation Oncology, ad hoc reviewer 2012-present Acta Oncologica, ad hoc reviewer 2012-present Journal of the National Cancer Institute, ad hoc reviewer 2012-present European Urology, ad hoc reviewer 2013-present Journal of Comparative Effectiveness Research, ad hoc reviewer 2013-present BMC Cancer, ad hoc reviewer 2013-present Clinical Oncology, ad hoc reviewer 2013-present Clinical Cancer Research, ad hoc reviewer 2014-present Annals of Oncology, ad hoc reviewer 2014-present Journal of Oncology Practice, ad hoc reviewer 2014-present JAMA, ad hoc reviewer 2014-present Journal of Urology, ad hoc reviewer 2014-present Journal of Geriatric Oncology, ad hoc reviewer Grant Reviews: 2012, 2013 Raymond and Maria Floyd Award for Bladder Cancer Research, Bladder Cancer

Advocacy Network (BCAN) 2012 Robert Wood Johnson Foundation/Changes in Health Care Financing and

Organization 2013 Department of Defense Prostate Cancer Research Program: review panel for

Laboratory-Clinical Translation Award

2014 UNC University Cancer Research Fund Innovation Award 2014 UNC KL2 (junior faculty training) grant review 2014 Department of Defense Prostate Cancer Research Program: review panel for

Population Science Impact Award 2014 Department of Defense Prostate Cancer Research Program: review panel for

Health Disparity Award 2014 Patient-Centered Outcomes Research Institute (PCORI) Pragmatic Clinical

Trials, methodological peer reviewer Teaching Experience: University of North Carolina: 2009-present Course director, Radiation Oncology Clerkship 2009-present Member, Residency Education Committee 2009-present School of Medicine Career Goal Advisor 2012-present School of Medicine Radiation Oncology Student Interest Group – Faculty Advisor 2013-present Faculty and Multidisciplinary Advisory Committee, Cancer Care Quality Training

Program (through School of Public Health) Harvard School of Public Health: 2008 Teaching Fellow, Decision Analysis for Clinical Research (RDS 286) 2008 Grader, Decision Analysis for Health and Medical Practices (RDS 280) Harvard Medical School:

2007 Nominated for Class of 2008 Teaching Award 2007-2009 Biomatrix: Harvard Medical School – MIT undergraduate mentoring program.

5

Suffolk University (Boston, MA): 2007, 2008 Lecturer, Oncology & Pathology (course for radiation therapy students) Mentoring (University of North Carolina): 2010-present Kevin Diao: Undergraduate student; Taylor Summer Undergraduate Research

Fellowship. (Now a medical student at Harvard) 2010-2012 Jordan Holmes: Medical student; Doris Duke Clinical Research Fellow. (Now a

radiation oncology resident at UNC) 2011-2013 Trevor Royce: Medical student; Doris Duke Clinical Research Fellow. (Now a

radiation oncology resident at Harvard) 2011-2013 William Stokes: Medical student; Holderness Distinguished Medical Scholar.

Deborah C Leary Award – most outstanding medical student research awarded at graduation. (Now a radiation oncology resident at University of Colorado)

2011-2013 Ian Allen: Medical student; Master’s degree (MPH) thesis advisor. (Now an internal medicine resident at Harvard – Massachusetts General Hospital)

2011-2013 Ying Hou: Medical student. (Now an Internal Medicine resident at University of Massachusetts)

2011-present Emily Lobos: Undergraduate student. Summer Undergraduate Research Fellowship.

2011-2013 Adam Kuykendal: Medical oncology fellow; National Research Service Award

(NRSA) Post-doctoral Fellow. (Now a medical oncologist at Levine Cancer

Institute)

2011-present Nathan Sheets: Radiation oncology resident; ASCO Young Investigator Award. (Now junior faculty at UNC)

2012-present Kevin Pearlstein: Medical student. (Now a radiation oncology resident at UNC) 2013-present Maili Lim: Undergraduate student.

2013-present Fan Ye: Medical student; Master’s degree (MPH) thesis advisor. (Now an anesthesia resident at University of Virginia)

2013-present Mark Waddle: Medical student. Deborah C Leary Award, honorable mention – most outstanding medical student research awarded at graduation. (Now a radiation oncology resident at Mayo-Jacksonville)

2014-present Jahan Mohiuddin: Medical Student; Holderness Distinguished Medical Scholar. 2014-present: Brock Baker: Medical student. Awards and Honors: 1996 Barry M. Goldwater Scholar 1999 Highest Distinction (equivalent to summa cum laude), University of Kansas 2000 Harvard Medical School PASTEUR Fellow – Patient-Associated Science:

Training, Education, Understanding, and Research 2001 Leopold Schepp Foundation Scholarship 2001 Doris Duke Clinical Research Fellow 2004 Cum laude, Harvard Medical School 2006 Travel grant, American Society for Therapeutic Radiology and Oncology Health

Services/Outcomes Research in Oncology Symposium 2007 CaPSURE Scholar: UCSF Cancer of the Prostate Strategic Urologic Research

Endeavor 2008 Radiation Therapy Oncology Group (RTOG) Meeting Travel Grant 2009 ASCO Cancer Foundation Merit Award 2009 ASCO/AACR Methods in Clinical Research (Vail Workshop) 2010 University of North Carolina Junior Faculty Development Award 2011 Department of Radiation Oncology Excellence in Teaching Award

6

2012 UNC School of Medicine Academy of Educators Medical Student Research Mentor Award

2013 Inducted as Member of UNC School of Medicine Academy of Educators 2013 Association of Residents in Radiation Oncology (ARRO) Educator of the Year

(national award) 2013 UNC James W. Woods Junior Faculty Development Award (one per year) 2014 UNC Alpha Omega Alpha (AOA) Faculty Member inductee Funding Information:

2007-2008 Joint Center for Radiation Therapy Foundation Grant Coronary heart disease and stroke risk associated with breast cancer irradiation based on patient baseline cardiac risk profile. Total costs: $31,333 Role: Primary Investigator Faculty advisor: Jay Harris, MD

2009-2012 University of North Carolina Institutional KL2 grant Total funding: $50,000/year for salary support, $25,000/year for research Role: Scholar Percent Effort: 50% 2009-2011 Contract: Agency for Healthcare Research and Quality (AHRQ) DeCIDE project

to evaluate the role of Positron Emission Tomography (PET) scans for renal cell carcinoma and pancreatic adenocarcinoma.

Total costs: $488,000 Role: Principal Investigator Percent Effort: 25% 2010-2013 Contract: Agency for Healthcare Research and Quality (AHRQ) DeCIDE project

to evaluate comparative effectiveness of management options for localized prostate cancer.

Direct costs: $2,282,610 Role: Principal Investigator Percent Effort: 35% 2010-2012 University Cancer Research Fund Innovation Award

Nanoparticle-loaded biodegradable spacers for local drug delivery in prostate Cancer Brachytherapy

Total costs: $150,000 Role: Co-Investigator 2011-2013 University Cancer Research Fund Innovation Award

Development and pilot test of the UNC Patient-Reported Symptom Monitoring System (PRSM) in the North Carolina Cancer Hospital to enhance quality of cancer care.

Total costs: $200,000 Role: Co-Investigator 2011-2012 University of North Carolina – Lineberger Comprehensive Cancer Center

Genitourinary Cancer Research Fund Prospective cohort study of localized prostate cancer Direct costs: $35,000 Role: Principal Investigator 2012-2013 North Carolina Translational & Clinical Sciences Institute (NC TraCS)

7

Primary care utilization and quality of life in prostate cancer survivors Direct costs: $49,350 Role: Principal Investigator 2012-2015 National Cancer Institute 2R44CA141941-02 CT image estimation for calculation of delivered dose Role: Co-Investigator. Percent Effort: 5% 2012-2014 Radiation Therapy Oncology Group (RTOG) CCOP Pilot Grant A study to evaluate cardiovascular risk factors and receipt of primary and

preventive care in prostate cancer patients who receive definitive radiation therapy and androgen deprivation therapy

Role: Principal Investigator Total costs: $100,000 2012-2014 Accuray, Inc.

Comparative effectiveness of management options for localized prostate cancer – parallel study to include patients treated with CyberKnife radiation therapy. Role: Principal Investigator Total costs: $100,000 Percent Effort: 0.5%

2012-2013 Health-e-NC Signature Initiative

Improving survivorship care through coordination, communication and support: enhance oncology-primary care communication.

Role: Co-Investigator Total cost: $207,154 2012-2014 Population Science Developmental Research Award

Survivorship care in long-term prostate cancer survivors – a population-based cohort study Role: Principal Investigator Total cost: $50,000

2012-2016 1R01CA174433-01

PROMIS validation in prospective population-based prostate cancer research study Role: Principal Investigator (with Reeve) Direct cost: $872,053 Percent Effort: 15% Administrative supplement awarded 9/12/14-9/11/13 for an additional $150,000

2013-2015 University Cancer Research Fund Innovation Award

Building and characterizing the North Carolina Bladder Cancer Cohort – defining quality of life and potential health care needs during survivorship

Total costs: $175,000 Role: Principal Investigator 2014-2016 A Survivorship Action Partnership – USA (Movember Foundation, LIVEStrong

Foundation) This is a consortium of 15 institutions across the US selected to design and

implement interventions to improve prostate cancer survivorship Total funding: $5.4 million Role: UNC Principal Investigator; Co-Lead for Survivorship Care Plan Team

8

Percent Effort: 20% 2014-2019 1R01HS022713-01A1 (declined due to overlap with PCORI grant below) NC ProCESS: a stakeholder-driven, population-based prospective cohort study

Role: Principal Investigator Direct cost: $822,276 Percent Effort: 20%

2014-2017 1R01EB020426-01 SCH: Proactive health monitoring using individualized analysis of tissue elasticity Role: Principal Investigator (with Lin, Jojic, Zhu) Direct cost: $509,509 Percent Effort: 4.2% 2015-2018 CER-1310-06453 (Patient-Centered Outcomes Research Institute/PCORI) North Carolina Prostate cancer Comparative Effectiveness & Survivorship Study

(NC ProCESS): A Stakeholder-Driven, Population-Based Prospective Cohort Study

Role: Principal Investigator Direct cost: $1,094,849 2015-2016 550KR101503 North Carolina Translational & Clinical Sciences Institute (NC TraCS) Aggressive end-of-life care among patients with cancer under age 65: analysis of

Healthcore Integrated Research Database Role: Principal Investigator Direct cost: $50,000 Primary Mentor for Grants Received: 2013-2014 American Society of Clinical Oncology (ASCO) Young Investigator Award

The impact of the availability of new surgical technology in a local community on referral patterns and receipt of care for localized prostate cancer, analysis of SEER-Medicare data

Total costs: $50,000 PI: Nathan Sheets, MD 2013-2014 Carolina Community Network Center Pilot Grant Disparity in receipt of multidisciplinary consultation and perceptions regarding

treatment options among African American and Caucasian prostate cancer patients

Total costs: $20,000 PI: Nathan Sheets, MD Bibliography Original Articles: 1. Talcott JA, Manola J, Clark JA, Kaplan I, Beard C, Mitchell SP, Chen RC, O’Leary M, Kantoff PW,

D’Amico AV. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 21:3979-86, 2003.

2. Chen RC, Clark JA, Manola J, Talcott JA. Treatment ‘mismatch' in early prostate cancer: do

treatment choices take patient quality of life into account? Cancer. 112(1):61-8, 2008. (editorial accompanied manuscript)

9

3. Chen RC, Lin NU, Golshan M, Harris JR, Bellon JR. Internal mammary nodes in breast cancer: diagnosis and implications for patient management – a systematic review. J Clin Oncol. 26(30):4981-9, 2008.

4. Chen RC, Sadetsky N, D’Amico AV, Chen MH, Carroll PR. Maximum versus mono androgen

blockade and the risk of PSA recurrence in men with localized or locally-advanced prostate cancer undergoing brachytherapy. Int J Radiat Oncol Biol Phys. 75(1):36-9, 2009.

5. Chen RC, Clark JA, Talcott JA. Individualizing quality of life outcomes reporting: how localized

prostate cancer treatments affect patients with different levels of baseline urinary, bowel and sexual function. J Clin Oncol. 27(24):3916-22, 2009. (editorial accompanied manuscript)

6. Nguyen PL, Chen RC, Clark JA, Cormack RA, Loffredo M, McMahon E, Nguyen AU, Suh WW,

Tempany CM, D’Amico AV. Patient-reported quality of life following salvage brachytherapy for radio-recurrent prostate cancer: a prospective phase II study. Brachytherapy. 8(4):345-52, 2009.

7. Chen RC, Chin MS, Ng AK, Feng Y, Neuberg D, Silver B, Pinkus GS, Stevenson MA, Mauch PM.

Early-stage lymphocyte-predominant Hodgkin lymphoma: patient outcomes from a large single-institution series with long follow-up. J Clin Oncol. 28(1):136-41, 2010.

8. Chen RC, Mamon HJ, Chen YH, Gelman RS, Suh WW, Talcott JA, Clark JW, Hong TS. Patient-

reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer. Cancer. 116(8):1879-86, 2010.

9. Nguyen PL, Chen RC, Hoffman KE, Trofimov A, Efstathiou JA, Coen JJ, Shipley WU, Zietman AL,

Talcott JA. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life following conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int J Radiat Oncol Biol Phys. 78(4):1081-5, 2010.

10. Hoffman KE, Nguyen PL, Chen MH, Chen RC, Choueri TK, Hu JC, Kuban DA, D’Amico AV. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol. 185(1):116-20, 2011.

11. Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR,

Bartlett NJ, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Rudek MA, Soares E, Cai S, Dancey J, McLeod HL, Piwnica-Worms H. A phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Canc Chemother Pharmacol. 67(6):1225-37, 2011.

12. Xie L, Saynak M, Veeramachaneni NK, Fried DV, Jagtap M, Chiu WK, Higginson DS, Lawrence MV,

Khandani AH, Qaqish BF, Chen RC, Marks LB. Prognostic significance of a positive FDG-PET in the mediastinum for patients with pathologic N0-1 non-small cell lung cancer. Radiology, 261(1):226,34, 2011.

13. Werner ME, Copp JA, Karve S, Cummings ND, Sukumar R, May R, Napier ME, Chen RC, Cox AD,

Wang AZ. Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy. ACS Nano, 22(5):8990-8, 2011.

14. Werner ME, Karve S, Sukumar R, Cummings ND, Copp JA, Chen RC, Zhang T, Wang AZ. Folate

targeted nanoparticle delivery of chemo- and radio-therapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials, 32(33):8548-54, 2011.

15. Nguyen PL, Chen MH, Hoffman KE, Chen RC, Hu J, Bennett C, Kattan M, Sartor O, Stein K,

D’Amico AV. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int, 110(2):201-5, 2012.

10

16. Higginson DS, Chen RC, Morris DE, Halle J, Rosenman JG, Socinski MA, Marks LB. Predicting the

need for palliative thoracic radiation following first-line chemotherapy for non-small cell lung carcinoma. Cancer, 118(10):2744-51, 2012.

17. Holmes, JA, Carpenter WR, Wu Y, Peacock S, Massing M, Schenck AP, Meyer AM, Diao K, Wheeler

SB, Stitzenberg KB, Chen RC. Impact of distance to an urologist on early diagnosis of prostate cancer among black and white patients. J Urol., 187(3):883-8, 2012.

18. Song L, Mishel M, Bensen JT, Chen RC, Knafl GJ, Blackard B, Farnan L, Fontham E, Su LJ,

Brennan CS, Mohler JL, Godley PA. How does health literacy affect quality of life among men with newly diagnosed clinically localized prostate cancer? Findings from the North Carolina-Louisiana Prostate Cancer Project (PCaP). Cancer, 118(15):3842-51, 2012.

19. Holmes JA, Wang ZA, Hoffman KE, Hendrix LH, Rosenman JG, Carpenter WR, Godley PA, Chen

RC. Is primary prostate cancer treatment influenced by likelihood of extraprostatic disease? A patterns of care study using the Surveillance Epidemiology and End Results database. Int J Radiat Oncol Biol Phys, 84(1):88-92, 2012.

20. Xie L, Fan M, Sheets NC, Chen RC, Jiang GL, Marks LB. The use of radiation therapy appears to

improve outcome in patients with malignant primary tracheal tumors: a SEER-based analysis. Int J Radiat Oncol Biol Phys, 84(2):464-70, 2012.

21. Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang YK, Sturmer T, Holmes JA, Reeve BB, Godley PA,

Carpenter WR, Chen RC. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA, 307(15):1611-20, 2012. (editorial accompanied manuscript)

22. Chen RC, Mamon HJ, Ancukiewicz M, Killoran JH, Crowley EM, Blaszkowsky LS, Wo JY, Ryan DP,

Hong TS. Dose-volume effects on patient-reported acute gastrointestinal symptoms during chemoradiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys, 83(4):e513-7, 2012.

23. Chen RC, Zhang Y, Chen MH, McMahon E, Loffredo M, McPherson CP, Nguyen AU, Nguyen PL,

D’Amico AV. Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial. BJU Int., 110(11):1690-5, 2012.

24. Henderson LM, Reeder-Hayes K, Hinton SP, Carpenter WR, Chen RC. Comparing physician-

reported cancer management plans with Medicare services received. Archives Int Med. (now called JAMA Int Med), 172(8):664, 2012.

25. Chen RC, Royce TJ, Extermann M, Reeve BB. Impact of age and comorbidity on treatment and

outcomes in elderly cancer patients. Seminars Radiat Oncol., 22(4):265-71, 2012.

26. Reeve BB, Stover AM, Jenson R, Chen RC, Taylor KL, Clauser SB, Collins SP, Potosky AL. Impact of prostate cancer diagnosis and treatment on health-related quality of life for older Americans: a population-based study. Cancer, 118(22):5679-87, 2012.

27. Karve S, Werner ME, Sukumar R, Cummings ND, Copp JA, Wang EC, Li C, Chen RC, Pacold ME,

Wang AZ. Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc Natl Acad Sci, 109(20):8230-5, 2012.

28. Higginson DS, Chen RC, Tracton G, Morris DE, Halle J, Rosenman JG, Stefanescu M, Pham E,

Socinski MA, Marks LB. The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys., 84(3):e385-92, 2012.

11

29. Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang ZA, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen deprivation therapy (ADT) for high-risk prostate cancer. BJU International, 110(11 Pt B):E721-6, 2012.

30. Parthan A, Pruttivarasin N, Davies D, Taylor DC, Pawar V, Hassmiller KM, Chen RC. Comparative cost-effectiveness of Cyberknife stereotactic body radiation therapy (SBRT) treatment versus intensity-modulated and proton radiation therapy for localized prostate cancer. Frontiers Radiat Oncol., 2:81 (page 1-9), 2012.

31. Song L, Chen RC, Bensen JT, Knafl GJ, Nielsen ME, Farnan L, Wallen EM, Mishel M, Pruthi RS,

Mohler JL, Godley PA. Who makes the decision regarding treatment for prostate cancer, patient or physician? Results from a population-based study. Cancer, 119(2):421-8, 2013. Featured on journal cover.

32. Ellis SD, Blackard B, Carpenter WR, Mishel M, Chen RC, Godley PA, Mohler JL, Bensen JT. Receipt

of National Comprehensive Cancer Network guideline-concordant prostate cancer care among African American and Caucasian American men in North Carolina. Cancer, 119(12):2282-90, 2013. (editorial accompanied manuscript)

33. Kuykendal AR, Hendrix LH, Salloum RG, Godley PA, Chen RC. Guideline-discordant androgen

deprivation therapy in localized prostate cancer: patterns of use in the Medicare population and cost implications. Ann Oncol., 24(5):1338-43, 2013.

34. Stokes WA, Hendrix LH, Royce TJ, Allen IM, Godley PA, Wang AZ, Chen RC. Racial differences in

time from prostate cancer diagnosis to treatment initiation, a population-based study. Cancer, 119(13):2486-93, 2013. [selected by journal for press release]

35. Church JA, Adams RD, Hendrix LH, Holmes JA, Marks LB, Chen RC. National study to determine the

comfort levels of radiation therapists and medical dosimetrists to report errors. Pract Radiat Oncol, 3(4):e165-70, 2013.

36. Greenberg CC, Wind JK, Chang GJ, Chen RC, Schrag D. Stakeholder engagement for comparative

effectiveness research in cancer care: experience of the DEcIDE Cancer Consortium. J Comp Eff Res, 2(2):117-25, 2013.

37. Goldin GH, Sheets NC, Meyer AM, Kuo TM, Wu Y, Sturmer T, Godley PA, Carpenter WR, Chen RC.

Comparative effectiveness of intensity modulated radiation therapy and conventional conformal radiation therapy in the treatment of prostate cancer after radical prostatectomy. JAMA Int Med., 173(12):1136-43, 2013. (editorial accompanied manuscript)

38. Chen RC, Shipley WU, Efstathiou JA, Zietman AL. Trimodality bladder preservation therapy for

muscle-invasive bladder cancer. J Natl Compr Canc Netw, 11(8):952-60, 2013.

39. Efstathiou JA, Nassif DS, McNutt TR, Bogardus B, Bosch W, Carlin J, Chen RC, Chou H, Eggert D, Fraass BA, Goldwein J, Hoffman KE, Hotz K, Hunt M, Kessler M, Lawton CAF, Mayo C, Michalski JM, Mutic S, Potters L, Rose CM, Sandler HM, Sharp G, Tome W, Tran PT, Wall T, Zietman AL, Gabriel PE, Bekelman JE. Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract 9:e90-e95, 2013.

40. Sheets NC, Hendrix LH, Allen IM, Chen RC. Trends in use of post-prostatectomy therapies for

patients with prostate cancer, a surveillance, epidemiology, and end results-Medicare analysis. Cancer, 119(18):3295-301, 2013.

12

41. Pearlstein KA, Chen RC. Comparing dosimetric, morbidity, quality of life, and cancer control outcomes after 3D conformal, intensity-modulated, and proton radiation therapy for prostate cancer. Semin Radiat Oncol 23(3):182-90, 2013.

42. White AJ, Reeve BB, Chen RC, Stover AM, Irwin DE. Urinary incontinence and health-related quality

of life among older Americans with and without cancer: a cross-sectional study. BMC Cancer, 13:377 (pages 1-9), 2013.

43. Xu Z, Chen RC, Wang AZ, Kress A, Foskey M, Cullip T, Tracton G, Chang S, Chaney E. Comparison of user-directed and fully automatic methods for mapping a radiation beam isocenter from planning to treatment space in image-guided radiotherapy for prostate cancer. Int J Biomed Imag, 2013 (article ID 892152).

44. Falchook AD, Salloum RG, Hendrix LH, Chen RC. Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs. Int J Radiat Oncol Biol Phys.89(2):243-8, 2014.

45. Gallagher SA, Smith A, Matthews JE, Potter CW, Woods ME, Raynor M, Wallen EM, Rathmell WK,

Whang YE, Kim WY, Godley PA, Chen RC, Wang A, Chaochen Y, Barocas DA, Pruthi RS, Nielsen ME, Milowsky MI. Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary Oncology Database – UNC GOLD. Urol Oncol 32(1):e1-9, 2014.

46. Chen RC. Comparative effectiveness research in oncology: the promise, challenges and opportunities. Seminars Radiat Oncol, 24(1):1-4, 2014.

47. Meyer AM, Wheeler SB, Weinberger M, Chen RC, Carpenter WR. An overview of methods for

comparative effectiveness research. Seminars Radiat Oncol, 24(1):5-13, 2014.

48. Chen RC, Hendrix LH, Carpenter WR, Bainbridge J, Wang ZA, Nielsen ME, Godley PA. Receipt of guideline-concordant treatment in elderly prostate cancer patients. Int J Radiat Oncol Biol Phys.88(2):332-8, 2014.

49. Lavender C, Miller S, Church J, Chen RC, Muresan PA, Adams RD. Fostering a culture of interprofessional education for radiation therapy and medical dosimetry students. Med Dosim 39(1):50-3, 2014.

50. White AJ, Reeve BB, Chen RC, Stover AM, Irwin DE. Coexistence of urinary incontinence and major depressive disorder on health-related quality of life among older Americans with and without cancer. J Cancer Survivorship, 8(3):497-507, 2014.

51. Talcott JA, Manola J, Chen RC, Clark JA, Kaplan I, D’Amico AV, Zietman AL. Using patient-reported outcomes to assess and improve prostate cancer brachytherapy. BJU Int, 114(4):511-6, 2014.

52. Smith AB, Deal AM, Woods ME, Wallen EM, Pruthi RS, Chen RC, Milowsky MI, Nielsen ME. Muscle-

invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. BJU Int, 114(5):719-26, 2014.

53. Reeve BB, Chen RC, Moore DT, Deal AM, Usinger DS, Lyons JC, Talcott JA. Impact of comorbidity

on health-related quality of life after prostate cancer treatment: combined analysis of two prospective cohort studies. BJU Int, 114(6b):E74-81, 2014.

54. Chen RC, Chang P, Vetter RJ, Lukka H, Stokes WA, Sanda MG, Watkins-Bruner D, Reeve BB,

Sandler HM. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. J Natl Cancer Inst, 106(7): pii, 2014.

13

55. Royce TJ, Hendrix LH, Stokes WA, Allen IM, Chen RC. Rates of cancer screening in older individuals with different life expectancies in the United States. JAMA Intern Med, 174(10):1558-65, 2014. Editorial accompanied article.

56. Mayer DK, Birken SA, Check DK, Chen RC. Summing It Up: An Integrative Review of Studies of

Cancer Survivorship Care (SCP) Plans (2006-2013). Cancer, ePub 2014.

57. Jagsi R, Bekelman J, Chen A, Chen RC, Hoffman KE, Shih YT, Smith BD, Yu JB. Considerations for observational research using large datasets in radiation oncology. Int J Radiat Oncol Biol Phys., 90(1):11-24, 2014.

58. Basch E, Loblaw DA, Oliver TK, Bennett C, Carducci M, Chen R, Frame J, Garrels K, Hotte S, Kattan

M, Nam R, Raghavan D, Saad F, Taplin ME, Walker-Dilks C, Williams J, Winquist E, Wooten T, Virgo K. Systemic therapy in men with metastatic castrate-resistant prostate cancer (CRPC): American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. J Clin Oncol, 32(30):3436-48, 2014.

59. Song L, Weaver MA, Chen RC, Bensen JT, Fontham E, Su LS, Mohler JL, Mishel M, Godley PA,

Sleath B. Associations between patient-provider communication and socio-cultural factors in prostate cancer patients: a cross-sectional evaluation of racial differences. Patient Education Counseling, 97(3):339-46, 2014.

60. Reeder-Hayes K, Freburger J, Feaganes J, Peacock S, Henderson L, Massing M, Schenck AP,

Stearns SC, Carpenter WR, Chen RC, Khandani AH. FDG-PET in the follow-up of pancreatic cancer: effects on mortality and treatment intensity. J Comparat Effect Res, 3(5):491-502, 2014.

61. Waddle MR, Chen RC, Arastu NH, Green RL, Jackson M, Qaqish BF, Camporeale J, Collichio FA,

Marks LB. Unanticipated hospital admissions in patients undergoing radiotherapy with or without concurrent chemotherapy: incidence and predictive factors. Practi Radiat Oncol, Epub.

62. Freedland SJ, Rumble RB, Finelli A, Chen RC, Slovin S, Stein M, Mendelson D, Wackett C, Sandler

H. Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol, 32(34):3892-8, 2014.

63. Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A, Blute M, Catto J, Chen RC,

D’Amico AV, Feick G, Fitzpatrick JM, Frank SJ, Froehner M, Frydenberg M, Glaser A, Graefen M, Hamstra D, Kibel A, Mendenhall N, Moretti K, Ramon J, Roos I, Sandler H, Sullivan FJ, Swanson D, Tewari A, Vickers A, Wiegel T, Huland H. Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol, Epub.

64. Meyer AM, Kuo TM, Carpenter WR, Chen RC, Sturmer T. Using procedural codes to define radiation

toxicity in administrative data: the devil is in the details. Med Care, Epub, 2014.

65. Jagsi R, Falchook AD, Hendrix LH, Curry H, Chen RC. Adoption of hypofractionated radiotherapy for breast cancer after publication of randomized trials. Int J Radiat Oncol Biol Phys, 90(5):1001-9, 2014.

66. Chen RC, Carpenter WR, Kim M, Hendrix LH, Agans RP, Meyer AM, Hoffmeyer A, Reeve BB,

Nielsen ME, Usinger DS, Strigo TS, Jackman AM, Anderson M, Godley PA. Design of the North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS). J Comparat Effect Res, 4(1):3-9, 2015.

67. Falchook AD, Chen RC. Association between certificate of need legislation and radiotherapy use

among elderly patients with low risk cancers. Int J Radiat Oncol Biol Phys, Epub 2015.

14

68. Pinheiro L, Wheeler S, Chen RC, Mayer D, Carpen JM, Reeve BB. The effects of cancer and racial disparities in health-related quality of life among older Americans: a case-control, population-based study. Cancer, accepted.

69. Cobran EK, Overman R, Chen RC, Meyer AM, Kuo M, O’Brien J, Sturmer T, Sheets NC, Goldin GH,

Pen D, Godley PA, Carpenter WR. Racial disparities in diffusion, comparative morbidity, and disease control of intensity-modulated radiation therapy compared to conformal radiation therapy for localized prostate cancer. Am J Men Health, accepted.

70. Falchook A, Hendrix L, Chen RC. Guideline discordant utilization of imaging during workup of newly-

diagnosed prostate cancer. J Oncol Pract, accepted.

71. Mayer DK, Green M, Check DK, Gerstel A, Chen RC, Asher G, Wheeler SB, Henson LC, Rosenstein DL. Is there a role for survivorship care plans in advanced cancer? Support Care Cancer, ePub 2015.

72. Mohiuddin JJ, Baker BR, Chen RC. Radiotherapy for high-risk prostate cancer. Nat Reviews Urol,

accepted.

73. Blackard B, Farnan L, Song L, Addington EL, Mishel M, Mohler JL, Chen RC, Nielsen ME, Bensen JT. Treatment decisional regret among men with prostate cancer: racial differences and influential factors in the North Carolina Health Access and Prostate Cancer Treatment Project (HCaP-NC). Cancer, accepted.

74. Caster J, Falchook AD, Hendrix LH, Chen RC. Risk of pathologic upgrading or locally advanced

disease in early prostate cancer patients based on biopsy Gleason score and PSA, a population-based study of modern patients. Int J Radiat Oncol Biol Phys, accepted.

75. Song L, Barbosa BD, Heineman RG, Symes Y, Tatum K, Greene G, Weaver WA, Chen RC.

Involvement in treatment decision-making and satisfaction with care among partners of patients with newly diagnosed localized prostate cancer. Oncol Nurs Forum, accepted.

Other Publications: 1. Fayda M, Chen R. Axillary vs. sentinel lymph node dissection for invasive breast cancer. JAMA.

305(22):2289, 2011. Letter to the editor.

2. Chen RC. Guideline-adherent care vs. quality care in cancer patients: twins or distant cousins? JAMA Intern Med 173(7):569-70, 2013. Invited editorial.

3. Chen RC. Making individualized decisions in the midst of uncertainties: the case of prostate cancer

and biochemical recurrence. Eur Urol 64(6):916-8, 2013. Invited editorial.

4. Hamstra DA, Chen RC. Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst, 106(3):djt463, 2014. Letter to the editor.

5. Chen RC, Zietman AL. A one-sided comparison – how methodologic problems can make radical

prostatectomy seem better than not having prostate cancer at all. ASCO Post 5(6), 2014. Invited commentary.

6. Chen RC, Hamstra DA, Sandler HM, Zietman AL. Comparative “complications” of radical

prostatectomy and radiotherapy? Lancet Oncol 15(4):e150, 2014. Correspondence. 7. Chen RC. Toward safe and high quality care through peer review in Radiation Oncology: need for

more evidence. Pract Radiat Oncol, 4(5):285-7, 2014. Invited editorial.

15

8. Chen RC. Organ preservation – will data translate into reality for bladder cancer patients? Clin Oncol. Invited editorial.

9. Chen RC. Post-prostatectomy radiotherapy, whether and how long to give concurrent androgen

deprivation therapy? Eur Urol. Invited editorial. Invited Talks: 1. “Advances in radiation treatment for prostate cancer.” Landes Symposium (University of North

Carolina at Chapel Hill). June 25, 2010. (Chapel Hill, NC)

2. “For prostate radiation treatments a non-ionizing imaging system is a better IGRT technology than an imaging system that uses ionizing radiation.” North Carolina IMRT/IGRT Symposium. October 2, 2010. (Raleigh, NC)

3. “Comparative effectiveness of management for localized prostate cancer.” The Alliance Summer Group Meeting. Comparative Effectiveness Working Group. June 25, 2011. (Boston, MA)

4. “Advanced in radiotherapy and decision making support.” Living with and Beyond Prostate Cancer

(Sponsored by Prostate Cancer Coalition of North Carolina). September 10, 2011. (Cary, NC)

5. “North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study.” Association of NC Cancer Registrars (ANCCR) Annual Meeting. September 14, 2011. (Winston-Salem, NC)

6. “Prostate cancer PRO expert perspective.” NCI Symptom Management and Quality of Life Steering

Committee Clinical Trials Planning Meeting on Building Bridges: the Identification of Core Symptom and Health-Related Quality of Life Domains for use in Cancer Research. September 23, 2011. (Washington, DC)

7. “Evaluation and management of bladder cancer.” Annual Meeting of the American Society for

Radiation Oncology (ASTRO). Educational session. October 4, 2011. (Miami, FL)

8. “Radiation techniques for prostate cancer.” Urology Grand Rounds. University of North Carolina at Chapel Hill. March 14, 2012. (Chapel Hill, NC)

9. “Indications for Cyberknife radiation.” UNC Cancer Network TeleHealth Medicine Lecture. May 23,

2012. (Chapel Hill, NC)

10. “Advances in radiation treatment for prostate cancer.” Landes Symposium (University of North Carolina at Chapel Hill). June 25, 2012. (Chapel Hill, NC)

11. “Multidisciplinary management of bladder cancers.” 22

nd Annual Hematology/Oncology Reviews.

Mayo Clinic. August 10, 2012. (Amelia Island, Florida)

12. “Treatment of muscle-invasive bladder cancer with chemoradiation,” 24th Annual Fall Foliage Cancer

Conference. October 19-20, 2012. (Asheville, NC)

13. “Cancer survivorship: multidisciplinary care of patients after treatment completion.” Moderator and panelist. Scientific Panel Session, Annual Meeting of the American Society for Radiation Oncology. October 28, 2012. (Boston, MA)

14. “Coverage with evidence development, example from the National Oncology PET Registry.” Dana-

Farber Cancer Institute Outcomes Research Seminar. October 30, 2012. (Boston, MA)

16

15. “Patient reported outcomes: ‘hearing the patient’s voice’ in a user-friendly and meaningful way.” Faculty panelist. Scientific Panel Session, Annual Meeting of the American Society for Radiation Oncology. October 31, 2012. (Boston, MA)

16. “Potential Alliance GU outcomes research opportunities.” The Alliance for Clinical Trials in Oncology

meeting. November 17, 2012. (Chicago, IL)

17. “Which modality is best? A comparative effectiveness approach.” Annual Meeting of the Society of Urologic Oncology. November 29, 2012. (Bethesda, MD)

18. “Radiation for renal cell carcinoma.” Mid Atlantic Patient and Survivor Conference. Kidney Cancer

Association. February 23, 2013. (Chapel Hill, NC)

19. “PRO from a clinician’s perspective: incorporating endpoints that help physicians help patients.” PROFICIENCY annual conference. April 11, 2013. (Hollywood, FL)

20. “Prostate cancer roundtable.” Third Annual Association for Value-Based Cancer Care Conference.

May 2, 2013. (Hollywood, FL)

21. “Comparative effectiveness and costs of proton therapy.” Faculty. Education Session, Annual Meeting of the American Society of Clinical Oncology. June 2, 2013. (Chicago, IL)

22. “Comparative effectiveness and patient-reported outcomes in localized prostate cancer.” Landes

Symposium (University of North Carolina at Chapel Hill). June 21-22, 2013. (Chapel Hill, NC)

23. “The impact of intensity-modulated proton therapy on proton therapy.” Scientific symposium faculty. Annual meeting of the American Association of Physicists in Medicine. August 5, 2013. (Indianapolis, IN)

24. “Radiation treatment advances in prostate cancer.” Keynote speaker. Living with and Beyond

Prostate Cancer (Sponsored by Prostate Cancer Coalition of North Carolina). September 7, 2013. (Raleigh, NC)

25. “Patient reported outcomes: ‘hearing the patient’s voice’ in a user-friendly and meaningful way.”

Faculty panelist. Scientific Panel Session, Annual Meeting of the American Society for Radiation Oncology. September 24, 2013. (Atlanta, GA)

26. “Survivorship issues for radiation therapy patients.” Faculty. Educational Session. Annual Meeting of

the American Society for Radiation Oncology. September 25, 2013. (Atlanta, GA)

27. “Advances in radiation treatment for prostate cancer.” Carolina Cancer Care Expo & Symposium. October 11, 2013. (Wilmington, NC)

28. “Best of journals: prostate cancer.” Genitourinary Cancers Symposium (ASCO GU). January 31,

2014. (San Francisco, CA)

29. “Proton therapy for prostate cancer: Con.” Annual meeting of the American College of Radiation Oncology. February 28, 2014. (Orlando, FL)

30. “Stereotactic body radiation therapy for prostate cancer.” UNC Cancer Network TeleHealth Medicine

Lecture. April 23, 2014. (Chapel Hill, NC)

31. “Multidisciplinary treatment of bladder cancer.” Annual Meeting of the American Society for Radiation Oncology (ASTRO). Educational session. September 15, 2014. (San Francisco, CA)

17

32. “Understanding the new evidence: a comparative effectiveness research primer for the radiation oncologist.” Annual Meeting of the American Society for Radiation Oncology (ASTRO). Educational session. September 15, 2014. (San Francisco, CA)

33. “Poster Walk with a Professor – Quality of Life.” Annual Meeting of the American Society for

Radiation Oncology (ASTRO). September 15, 2014. (San Francisco, CA)

34. “Role of post-operative radiation therapy for pN+ prostate cancer after prostatectomy.” Annual Meeting of the Society of Urologic Oncology. December 4, 2014. (Bethesda, MD)

35. “Linking broad based data from registries for quality assessment, comparative effectiveness, and

public health.” ASTRO NCI Big Data Workshop: Exploring Opportunities for Radiation Oncology in the Era of Big Data. August 13-14, 2015. (Bethesda, MD)

36. “Survivorship care: understanding the changing landscape and tools to implement SCPs.” Faculty.

Educational Session. Annual Meeting of the American Society for Radiation Oncology (ASTRO). October XX, 2015. (San Antonio, TX)

Conference Scientific Sessions: 1. Co-moderator, GU oral presentation session, Annual Meeting of the American Society for Radiation

Oncology. October, 2012. (Boston, MA)

2. Co-moderator, Patient Reported Outcomes oral presentation session. Annual Meeting of the American Society for Radiation Oncology. September 25, 2013. (Atlanta, GA)

3. Co-moderator, GU oral presentation session, Annual Meeting of the American Society for Radiation Oncology. September 14, 2014. (San Francisco, CA)

Books: 1. Kim SI, Swanson TA, Chen RC, editors. Underground Clinical Vignettes: Ob/Gyn, Classical Clinical

Cases for USMLE Step 2 and Clerkship Review, 4th Edition. Lippincott Williams & Wilkins, New York,

NY. [ISBN-10: 0781768403]

2. Chen RC, Section Editor. [A. Tewari, editor] Prostate Cancer: a Comprehensive Perspective, 1st

Edition. Springer, New York, NY. 2011. [ISBN-10: 144712863X] Book Chapters: 1. Chen RC, Mauch PM. [Specht and Yahalom, editors] Management of Lymphocyte-Predominant

Hodgkin Lymphoma. Radiotherapy for Hodgkin Lymphoma. Springer, New York, NY. 2010. [ISBN-10: 3540784551]

2. Chen RC, Holmes JA, D’Amico AV. Duration of Neoadjuvant/Adjuvant Androgen-Deprivation Therapy in Non-Metastatic Prostate Cancer. Radiation Medicine Rounds 2:1 (2011) 43-58. Demos Medical Publishing LLC. New York, NY. [ISBN-10: 1936287331]

3. Meyer J, Holmes JA, Chen RC. [A. Tewari, Editor] Proton beam therapy and novel radiotherapeutic

approaches. Prostate Cancer: a Comprehensive Perspective, 1st Edition. Springer, New York, NY.

2013. [ISBN-10: 144712863X]

4. Holmes JA, Chen RC. [A. Tewari, Editor] Radiotherapy plus hormonal therapy. Prostate Cancer: a Comprehensive Perspective, 1

st Edition. Springer, New York, NY. 2013. [ISBN-10: 144712863X]

18

5. Smith A, Balar AV, Milowsky MI, Chen RC. [Niederhuber, Armitage, Doroshow, Kastan, Tepper, Editors] Bladder cancer. Abeloff’s Clinical Oncology, 5

th Edition. Elsevier. [ISBN: 978-1-4557-2865-7]

6. D’Amico AV, Nguyen P, Crook JM, Chen RC, Koontz BF, Martin N, Lee WR, DeWeese TL. [Wein,

Kavoussi, Partin, Peters, Editors] Radiation therapy for prostate cancer. Wein: Campbell-Walsh Urology, 11

th Edition. Elsevier.

7. Baker BR, Mohiuddin JJ, Chen RC. Radiation with hormonal therapy. Prostate Cancer, 2

nd Edition.

Elsevier. Thesis: 1. Chen RC. “Developmental Therapeutic Strategies for UCN-01.” M.D. thesis, Harvard Medical School,

2004. Patents:

1. Wang Z, Werner M, Chen R, Byrne J, Karve S, Desimone J. Delivery for brachytherapy and associated methods. International PCT Patent Application No.: PCT/US2010/053357 (10/20/2010)

Abstracts: 1. Chen RC, Clark JA, Mitchell SP, Talcott JA. Treatment “mismatch” in early prostate cancer: an

empirical measure of patient-physician communication. J Clin Oncol 22:14s, 2004 (suppl: abstr 4566). ASCO Annual Meeting 2004. Poster discussion.

2. Chen RC, Clark JA, Mitchell SP, Talcott JA. Long-term outcomes after local treatments for prostate cancer by functional categories: late changes, different results. J Clin Oncol 24:18s, 2006 (suppl: abstr 4507). ASCO Annual Meeting 2006. Oral presentation.

3. Chen RC, Clark JA, Talcott JA. Treatment “mismatch” in early prostate cancer: do treatment choices

take patients’ quality of life into account? ASTRO Health Services/Outcomes Research in Oncology Symposium 2006. Poster presentation.

4. Chen RC, Fidias P, Yock TI, Niemierko A, Ancukiewicz M, Hong TS, Wolfgang JA, Gurubhagavatula

S, Choi NC. Treatment-related pneumonitis after concurrent cisplatin/etoposide and thoracic radiation therapy in lung cancer. IJROBP 66(3, supp1):S483, 2006. ASTRO Annual Meeting 2006. Poster presentation.

5. Chen RC, Zietman AL, D’Amico AV, Kaplan I, Clark JA, Manola J, Talcott JA. Using patient-reported

outcomes for technology assessment and quality improvement in prostate cancer brachytherapy. J Clin Oncol 25:18s, 2007 (suppl: abstr 5139). ASCO Annual Meeting 2007. Poster presentation.

6. Chen RC, Mamon HJ, Niemierko A, Crowley EM, Suh WW, Hong TS. Acute Quality of Life (QOL)

Effects of Chemoradiation Therapy (CRT) For Locally-Advanced Rectal Cancer. IJROBP 69(3, supp1):S284, 2007. ASTRO Annual Meeting 2007. Poster presentation.

7. Chen RC, D’Amico AV, Sadetsky N, Chen MH, Carroll PR. LHRH agonist with or without an

antiandrogen and the risk of prostate-specific antigen recurrence. The Genitourinary Cancers Symposium, 2008 (Abstract 203). Poster presentation.

8. Chen RC, Talcott JA. Long-term utilities after localized prostate cancer treatment: is treatment-related

dysfunction important? J Clin Oncol 26: 2008 (May 20 suppl: abstr 6546). ASCO Annual Meeting 2008. Poster presentation.

19

9. Chen RC, Chin MS, Ng AK, Silver B, Mauch PM. Lymphocyte-predominant Hodgkin lymphoma: patient outcomes from a large single-institutional series with long follow-up. IJROBP 72(1, supp 1):S123-124, 2008. ASTRO Annual Meeting 2008. Poster discussion.

10. Chen RC, Hankinson SE, Harris JR, Chen WY. Coronary heart disease (CHD) risk associated with

breast cancer (CA) irradiation (RT) based on patient baseline cardiac risk profile. J Clin Oncol 27:15s, 2009 (suppl: abstr 606). ASCO Annual Meeting 2009. Poster presentation. Merit award.

11. Chen RC, Punglia R, Sher DJ. Stereotactic radiosurgery (SRS) versus whole brain radiation therapy

(WBRT) versus combined treatment (SRS&WBRT) for brain metastases: a decision analysis. IJROBP 75(3, supp 1):S89, 2009. ASTRO Annual Meeting 2009. Oral presentation.

12. Chen RC, Chen MH, Zhang Y, McMahon E, Loffredo M, Nguyen AU, D’Amico AV. Patient-reported

quality of life (QOL) during radiation treatment (RT) utilizing an intra-rectal balloon for localized prostate cancer: results from a prospective phase II trial. The Genitourinary Cancers Symposium, 2010 (Abstract 226). Poster presentation.

13. Chen RC, Bainbridge J, Carpenter WR, Wang ZA, Nielsen ME, Darter J, Godley, PA. Racial differences in receipt of guideline-recommended treatment in men with low-, intermediate-, and high-risk prostate cancer (CaP), a population-based study. J Clin Oncol 28:15s, 2010 (suppl; abstr 9002). ASCO Annual Meeting 2010. Oral presentation.

14. Rosenman JG, Chen RC, Hoffman LG, Chiu WK, Pruthi RS, Wallen EM, Kim WY, Rathmell WK,

Godley PA, Whang YE. Phase I study of concurrent weekly docetaxel, androgen deprivation, and high-dose external beam radiation therapy (RT) for high-risk prostate cancer. IJROBP 78(3, supp 1):S126, 2010. ASTRO Annual Meeting 2010. Oral presentation.

15. Adams RD, Chen RC, Bailey JE, Marks LB. The willingness of dosimetrists and radiation therapists

to challenge physicians as a means of assuring patient safety: results of a pilot program. IJROBP 78(3, supp 1):S567-568, 2010. ASTRO Annual Meeting 2010. Poster presentation.

16. Chen RC, Chen MH, Zhang Y, McMahon E, Loffredo M, Nguyen PL, Beard CJ, D’Amico AV. Patient-

reported quality of life (QOL) in unfavorable-risk prostate cancer: sexual function recovery after external beam radiation (RT) and 6 months of androgen deprivation. IJROBP 78(3, supp 1):S603, 2010. ASTRO Annual Meeting 2010. Poster presentation.

17. Higginson DS, Chen RC, Socinski MA, Halle J, Marks LB. Rate of lobar collapse and/or urgent

thoracic RT following initial chemotherapy for advanced non-small cell carcinoma (NSCLC): implications for selecting patients for early intervention with thoracic RT. IJROBP 78(3, supp 1):S496-497, 2010. ASTRO Annual Meeting 2010. Poster presentation.

18. Xie L, Fried DV, Bailey JE, Chen R, DeMore N, Jones EL, Halle JS, Marks LB. Does the risk of late

radiation-associated malignancy offset the survival benefit of post-lumpectomy/mastectomy radiation for young women? A quantitative study based on SEER data. IJROBP 78(3, supp 1):S621, 2010. ASTRO Annual Meeting 2010. Poster presentation.

19. Lee H, Foskey M, Levy J, Saboo R, Tepper J, Chen R, Wang A, Chaney E. Calculation of dose

delivered to the prostate based on intra-treatment marker coordinates. IJROBP 78(3, supp 1):S683, 2010. ASTRO Annual Meeting 2010. Poster presentation.

20. Nguyen PL, Chen MH, Chen RC, Hoffman KE, Hu JC, Bennett CL, Kattan MW, Sartor AO, Stein K,

D’Amico AV. Comorbidity and treatment regret in men with recurrent prostate cancer. J Clin Oncol 29: 2011 (suppl 7; abstr 187). ASCO Annual Meeting 2011. Poster presentation.

21. Holmes JA, Carpenter WR, Wu Y, Peacock S, Massing M, Schenck AP, Meyer AM, Wheeler S,

Godley PA, Chen RC. Impact of travel distance on early diagnosis of prostate cancer (CaP) and

20

receipt of curative treatment. J Clin Oncol 29: 2011 (suppl; abstr 6129). ASCO Annual Meeting 2011. Poster presentation.

22. Holmes JA, Hendrix LH, Wang ZA, Hoffman KE, Rosenman JG, Carpenter WR, Godley PA, Chen

RC. Impact of the risk of extraprostatic disease on primary prostate cancer treatment, a patterns of care study using SEER. IJROBP 81(2, supp):S553, 2011. ASTRO Annual Meeting 2011. Poster presentation.

23. Church JA, Holmes JA, Adams RD, Hendrix LH, Jackson M, Chang SX, Burkhardt KD, Marks LB,

Chen RC. Assessing communication barriers to reporting errors in Radiation Oncology: results of a national survey of medical dosimetrists. IJROBP 81(2, supp):S559-60, 2011. ASTRO Annual Meeting 2011. Poster presentation.

24. Diao K, Yirmibesoglu E, Hoffman LG, Hendrix LH, Holmes JA, Hou Y, Xu ZS, Wang ZA, Chen RC.

Patient-reported quality of life (QOL) during image-guided intensity-modulated radiation therapy (IGRT) for localized prostate cancer. IJROBP 81(2, supp):S679, 2011. ASTRO Annual Meeting 2011. Poster presentation.

25. Goldin GH, Sheets NC, Meyer AM, Darter JD, Wu Y, Goyal R, Holmes JA, Godley PA, Carpenter

WR, Chen RC. Adoption of Intensity-Modulated Radiation Therapy (IMRT) Use for the Definitive and Post-Operative Treatments of Prostate Cancer, a SEER-Medicare Analysis. IJROBP 81(2, supp):S408, 2011. ASTRO Annual Meeting 2011. Poster presentation.

26. Sheets NC, Goldin GH, Meyer AM, Darter JD, Wu Y, Holmes JA, Reeve BB, Godley PA, Carpenter

WR, Chen RC. Comparative Long-Term Morbidity of Intensity-Modulated versus Conformal Radiation Therapy (RT) for Prostate Cancer, a SEER-Medicare Analysis. IJROBP 81(2, supp):S43, 2011. ASTRO Annual Meeting 2011. Oral presentation.

27. Wang Z, Karve S, Werner ME, Sukumar R, Tepper JE, Chen RC, DeSimone JM. Development of

nanoparticle-loaded drug eluting biodegradable spacers for prostate brachytherapy. IJROBP 81(2, supp):S144, 2011. ASTRO Annual Meeting 2011. Oral presentation.

28. Werner ME, Karve S, Copp JA, Cummings ND, Sukumar R, Chen RC, Cox AD, Napier ME, Wang

AZ. Folate-targeted nanoparticle formulation of docetaxel as an effective biologically targeted radiosensitizer of head and neck cancer. IJROBP 81(2, supp):S145, 2011. ASTRO Annual Meeting 2011. Oral presentation.

29. Chen RC, Sanda MG, Lukka H, Vetter RJ, Sandler HM. Recommended core set of patient-reported

health-related quality of life (HRQOL) domains in prostate cancer. International Society for Quality of Life Research (ISOQOL) Annual Meeting, 2011. Oral presentation.

30. Sheets NC, Goldin G, Meyer AM, Wu Y, Chang YK, Sturmer T, Holmes JA, Reeve BB, Godley PA,

Carpenter WR, Chen RC. Comparative effectiveness of intensity modulated radiation therapy (IMRT), proton therapy (PT), and conformal radiation therapy (CRT) in the treatment of localized prostate cancer. J Clin Oncol 30, 2012 (suppl 5;abstr 3). The Genitourinary Cancers Symposium 2012. Oral presentation. (Chosen as one of 5 abstracts for ASCO Media Session)

31. Ellis SD, Blackard B, Carpenter WR, Schroeder JC, Mishel M, Chen RC, Godley PA, Mohler JL,

Bensen JT. Prostate cancer guideline-concordance in a North Carolina population-based sample of African and Caucasian Americans. Academy Health 2012. Poster presentation.

32. Kuykendal A, Hendrix LH, Salloum R, Chen RC. Inappropriate use of androgen deprivation therapy in

localized prostate cancer. Academy Health 2012. Oral presentation.

21

33. Royce TJ, Todd J, Stokes WA, Allen IM, Chen RC. Life expectancy (LE) and the receipt of conservative vs. active treatment in men with prostate cancer (CaP): a population-based study. J Clin Oncol 30, 2012 (suppl; abstr 6032). ASCO Annual Meeting 2012. Poster discussion.

34. Stokes WA, Hendrix LH, Royce TJ, Allen IM, Wang AZ, Chen RC. Racial differences in delay of

treatment for localized prostate cancer (CaP), a population-based study. J Clin Oncol 30, 2012 (suppl; abstr 6037). ASCO Annual Meeting 2012. Poster discussion.

35. Goyal RK, Meyer AM, Sheets NC, Federspiel JJ, Carpenter WR, Chen RC, Biddle AK. Cost-utility of

proton therapy in the treatment of localized prostate cancer. J Clin Oncol 30, 2012 (suppl; abstr e15184). ASCO Annual Meeting 2012. Publication only.

36. Arastu NH, Chen RC, Jackson M, Green RL, Qaqish BF, Xu ZS, Collichio FA, Marks LB.

Unanticipated hospital admissions in patients undergoing radiotherapy with or without concurrent chemotherapy: incidence and predictive factors. J Clin Oncol 30, 2012 (suppl; abstr 6093). ASCO Annual Meeting 2012. Poster presentation.

37. Allen IM, Hendrix LH, Royce TJ, Stokes WA, Wang AZ, Godley PA, Chen RC. Prostate-specific

antigen (PSA) screening in the United States (US): patterns of use and PSA outcomes in screened vs. unscreened men. J Clin Oncol 30, 2012 (suppl; abstr 4658). ASCO Annual Meeting 2012. Poster presentation.

38. Kuykendal AR, Hendrix LH, Salloum RG, Godley PA, Chen RC. Guideline-discordant androgen

deprivation therapy (ADT) use in localized prostate cancer (CaP) and cost implications, a population-based study. J Clin Oncol 30, 2012 (suppl; abstr 4647). ASCO Annual Meeting 2012. Poster presentation.

39. Chen RC, Reeve BB, Moore DT, Deal A, Talcott JA. Association between baseline physical function

and comorbidity status with patient-reported quality of life after prostate cancer treatments: combined analysis of two prospective cohort studies. J Clin Oncol 30, 2012 (suppl; abstr 6107). ASCO Annual Meeting 2012. Poster presentation.

40. Arastu NH, Chen RC, Jackson M, Green RL, Xu ZS, Camporeale J, Collichio FA, Qaqish BF, Marks

LB. The incidence and factors associate with unplanned hospital admissions in patients receiving radiation therapy. IJROBP 84(3, supp):S99, 2012. ASTRO Annual Meeting 2012. Oral presentation.

41. Hou Y, Lobos E, Diao K, Hendrix LH, Willson AK, Mintz J, Miller SM, Wang AZ, Zhu XF, Chen RC.

Correlation between dose-volume parameters and patient-reported quality of life (QOL) during image-guided intensity-modulated radiation therapy (IGRT) for prostate cancer. IJROBP 84(3, supp):S212-3, 2012. ASTRO Annual Meeting 2012. Poster discussion. (Top 10 most viewed posters for meeting)

42. Diao K, Holmes JA, Hou Y, Hendrix LH, Hoffman LG, Mintz J, Cameron TW, Wang AZ, Chen RC.

Comparative patient-reported quality of life (QOL) during radiation therapy (RT) in patients receiving definitive RT vs. post-prostatectomy RT for prostate cancer. IJROBP 84(3, supp):S373, 2012. ASTRO Annual Meeting 2012. Poster presentation.

43. Xu ZS, Foskey MS, Cullip TJ, Kress A, Tracton GS, Chen RC, Wang ZA, Chang S, Chaney EL.

Comparison of automatic and user-guided methods for isocenter mapping. IJROBP 84(3, supp):S772-3, 2012. ASTRO Annual Meeting 2012. Poster presentation.

44. Sheets NC, Allen IM, Hendrix LH, Chen RC. Trends in use of post-prostatectomy therapies for

prostate cancer, a SEER-Medicare analysis. IJROBP 84(3, supp):S544, 2012. ASTRO Annual Meeting 2012. Poster presentation.

22

45. Stokes WA, Hendrix LH, Royce TJ, Allen IM, Chen RC. Control of cardiovascular risk factors in cancer survivors compared to non-cancer controls, measured outcomes from a population-based study. IJROBP 84(3, supp):S543-4, 2012. ASTRO Annual Meeting 2012. Poster presentation.

46. Royce TJ, Hendrix LH, Stokes WA, Allen IM, Chen RC. Does patient life expectancy affect receipt of

routine cancer screening in the United State? A population-based study. IJROBP 84(3, supp):S122, 2012. ASTRO Annual Meeting 2012. Oral presentation.

47. Goldin GG, Zagar TM, Fayda M, Marks LB, Fried D, Miller SM, Rosenberg LA, Chen RC, Schreiber

EC, Morris DE. Clinical outcomes of Cyberknife radiosurgery for early stage lung cancer: low chest wall toxicity rates associated with tracking. Multidisciplinary Symposium in Thoracic Oncology 2012. Poster presentation.

48. Church JA, Adams RD, Hendrix LH, Holmes JA, Marks LB, Chen RC. The negative impact of prior

reprimand on radiation oncologists’ and dosimetrists’ comfort in reporting errors: results from a national survey of >500 respondents. J Clin Oncol 30, 2012 (suppl 34; abstr 204). ASCO Quality Care Symposium 2012. Poster presentation.

49. Chen RC, Carpenter WR, Hendrix LH, Wang ZA, Nielsen ME, Godley PA. Receipt of guideline-

concordant treatment in elderly African American and Caucasian prostate cancer patients. J Clin Oncol 30, 2012 (suppl 34; abstr 222). ASCO Quality Care Symposium 2012. Poster presentation.

50. Efstathiou JA, Nassif D, Chen RC, Hoffman KE, Kuban DA, Lawton CA, Michalski JM, Potters L,

Rose CM, Sandler HM, Suh W, Wall T, Zietman AL, Bekelman JE. National radiation oncology registry: the pilot prostate cancer registry. J Clin Oncol 30, 2012 (suppl 34; abstr 267). ASCO Quality Care Symposium, 2012. Poster presentation.

51. Arastu NH, Chen RC, Jackson M, Green RL, Qaqish BF, Xu ZS, Camporeale J, Collichio FA, Marks

LB. Unanticipated hospital admissions in patients undergoing radiotherapy with or without concurrent chemotherapy: incidence and predictive factors. J Clin Oncol 30, 2012 (suppl 34; abstr 114). ASCO Quality Care Symposium, 2012. Poster presentation.

52. Chen RC, Pruttivarasin N, Davies D, Taylor DC, Pawar V, Bijlani A, Lich KH, Parthan A. Comparative

cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Advancing Radiation Oncology: a Collaborative Forum, 2012. Poster presentation.

53. Goldin G, Diao K, Hendrix L, Hoffman LG, Mintz J, Lobos E, Wang A, Chen R. Patient reported

quality of life (QOL) with image-guided intensity-modulated radiation therapy (IMRT) in patients receiving definitive and post-prostatectomy radiation therapy (RT) for prostate cancer. Southeastern Section of the American Urological Association Annual Meeting, 2013. Moderated poster session.

54. Barbosa BB, Hendrix LH, Pearlstein KA, Chen RC. Treatment patterns for patients with localized (T1-

T2) penile squamous cell carcinoma in the United States. J Clin Oncol 31, 2013 (suppl 6; abstr 332). The Genitourinary Cancers Symposium, 2013. Poster presentation.

55. Pearlstein KA, Hendrix LH, Royce TJ, Stokes WA, Chen RC. Prevalence of cardiovascular disease

(CVD) risk factors and receipt of preventive care among prostate cancer (CaP) survivors in the United States. J Clin Oncol 31, 2013 (suppl 6; abstr 185). The Genitourinary Cancers Symposium, 2013. Poster presentation.

56. Chen RC, Nielsen ME, Reeve BB, Hendrix LH, Agans RP, Hoffmeyer A, Usinger D, Strigo T,

Jackman A, Godley PA. Perceptions regarding prostate cancer (CaP) treatment options, results from the North Carolina Prostate cancer Comparative Effectiveness & Survivorship Study (NC ProCESS). J Clin Oncol 31, 2013 (suppl; abstr 6530). ASCO Annual Meeting 2013. Poster discussion.

23

57. Falchook AD, Salloum RG, Hendrix LH, Chen RC. Use of bone scans during initial prostate cancer (CaP) workup, downstream procedures and associated Medicare costs. J Clin Oncol 31, 2013 (suppl; abstr 5040). ASCO Annual Meeting 2013. Poster presentation. [Resident received ASCO Merit Award]

58. Pearlstein KA, Hendrix LH, Chen RC. Prevalence of cardiovascular disease (CVD) risk factors and

preventive care among US cancer survivors. J Clin Oncol 31, 2013 (suppl; abstr 9592). ASCO Annual Meeting 2013. Poster presentation.

59. Goldin GH, Carter J, Zagar T, Fayda M, Prasad S, Fakiris A, Chen R, Morris D, Marks L, Schreiber E.

Stereotactic body radiotherapy for early stage lung cancer: quantifying the effect of tracking with respiratory motion on chestwall dosimetry. IJROBP 87(2, supp):S733-4, 2013. ASTRO Annual Meeting 2013. Poster presentation.

60. Pearlstein KA, Hendrix LH, Chen RC. Patient-level characteristics of Medicare patients in the United

States, implications for treatment and survivorship. IJROBP 87(2, supp):S176, 2013. ASTRO Annual Meeting 2013. Poster discussion.

61. Chen RC, Carpenter WR, Reeve BB, Hendrix LH, Meyer AM, Usinger DS, Strigo TS, Jackman AM,

Godley PA. Barriers to receiving radiation therapy for localized prostate cancer (CaP), results from the North Carolina Prostate cancer Comparative Effectiveness & Survivorship Study (NC ProCESS). IJROBP 87(2, supp):S179-80, 2013. ASTRO Annual Meeting 2013. Poster discussion.

62. Falchook AD, Salloum RG, Hendrix LH, Chen RC. Multiple pathology reviews in prostate cancer

diagnosis, prevalence of use in the Medicare population, and cost implications. IJROBP 87(2, supp):S40, 2013. ASTRO Annual Meeting 2013. Oral presentation. Selected for meeting Press Program (declined). [Resident received merit award as a top abstract]

63. Chen RC, Wong D, Underhill K, Medberry C, Fuller DB. Quality of life (QOL) outcomes through 3

years after stereotactic body radiation therapy (SBRT) for early prostate cancer, results from a multi-institutional Phase II trial. IJROBP 87(2, supp):S73, 2013. ASTRO Annual Meeting 2013. Oral presentation.

64. Chera BS, Parikh A, Caster J, Zagar T, Chen R, Sasaki-Adams D, Adunka O, Ewend M, Schreiber E.

Effect of node and beam-reduction optimization on the integral dose to the brain for robotic radiosurgery brain cases. Int J Radiat Oncol Biol Phys 87(2, supp):S281, 2013. ASTRO 2014. Poster presentation.

65. Cobran EK, Overman R, Carpenter WR, Godley PA, Chen RC. Racial disparities in diffusion,

comparative morbidity, and disease control of intensity-modulated radiation therapy compared to conformal radiation therapy for localized prostate cancer. Value in Health 16(7), A396, 2013. International Society for Pharmacoeconomics and Outcomes Research 2013. Poster presentation.

66. Pearlstein KA, Hendrix LH, Chen RC. Quality cancer-survivorship care: receipt of guideline-

recommended cardiovascular disease (CVD) preventive care among healthy cancer survivors in the United States. J Clin Oncol 31, 2013 (suppl 31; abstr 108). ASCO Quality Care Symposium 2013. Poster presentation.

67. Falchook AD, Hendrix LH, Chen RC. Guideline discordance in the use of radiographic imaging during

initial work-up of patients with prostate cancer (CaP). J Clin Oncol 31, 2013 (suppl 31; abstr 109). ASCO Quality Care Symposium 2013. Poster presentation. [Resident received ASCO Merit Award]

68. Falchook AD, Hendrix LH, Chen RC. Clinical implications of bone scan underuse for patients with

high-risk prostate cancer (CaP). The Genitourinary Symposium 2014. Poster presentation.

24

69. Smith A, Borse M, Modebe N, Nielsen M, Pruthi R, Johnson DC, Wallen EM, Woods MM, Milowsky MI, Chen RC, Biddle AK. Cost-utility analysis of cystectomy vs. chemo-radiation for treatment of muscle-invasive bladder cancer in the elderly. Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research 2014. Poster presentation.

70. Savitz S, Chen RC, Sher DJ. Cost-effectiveness analysis of neurocognitive-sparing treatments for

brain metastases. Academy Health 2014. Poster presentation.

71. Mayer DK, Green M, Check D, Gerstel A, Chen RC, Asher G, Wheeler SB, Hanson L, Rosenstein DL. Is there a role for survivorship care plans (SCP) in advanced cancer? 7

th Biennial Cancer

Survivorship Research Conference. Poster presentation.

72. Mayer DK, Birken SA, Check DK, Chen RC. An integrative review of survivorship care plans (SCP) (2006-2013). 7

th Biennial Cancer Survivorship Research Conference. Poster presentation.

73. Eblan MJ, Chen RC, Hendrix LH, Jones E. Population-based analysis of mortality over time in

endometrial cancer. ASCO 2014. Poster presentation. [Resident received Travel Award]

74. Sheets NC, Hendrix LH, Chen RC. Population-based analysis of treatment receipt in prostate cancer patients who initially pursued active surveillance (AS). ASCO 2014. Poster discussion.

75. Talcott JA, Clark JA, Manola J, Chen RC, Kaplan ID, Zietman AL, D’Amico AV. Prostate

brachytherapy technique and long-term urinary incontinence: 5-year outcomes of a prospective comparative cohort study. Submitted to ASCO 2014.

76. Chen RC, Falchook AD, Hendrix LH, Jagsi R. Adoption of hypofractionated radiotherapy for early

stage invasive breast cancer after publication of randomized trials. ASCO 2014. Poster discussion.

77. Falchook AD, Hendrix LH, Jagsi R*, Chen RC* [co-senior author]. Adoption of hypofractionated radiotherapy (HyRT) for ductal carcinoma in situ (DCIS): A SEER-Medicare study. ASCO 2014. Oral presentation. [Resident received ASCO Merit Award]

78. Waddle MR, Green RL, Ye F, Arastu NH, Collichio FA, Camporeale J, Marks LB, Chen RC.

Unanticipated hospital admissions in patients undergoing palliative radiotherapy (RT) with or without concurrent chemotherapy. ASCO 2014. Publication only.

79. Ye F, Hendrix LH, Waddle WR, Chen RC. Population-based evaluation of treatment patterns and survival of localized prostate cancer (CaP) patients with high prostate-specific antigen (PSA). ASCO 2014. Publication only.

80. Falchook AD, Hendrix LH, Curry HA, Chen RC*, Jagsi R* [co-senior author]. Adoption of intensity-

modulated radiotherapy (IMRT) in early-stage breast cancer patients receiving hypofractionated and conventionally fractionated radiation in the US. ASTRO 2014. Poster presentation.

81. Miller SM, Baker BR, Canasi D, Somasundaram V, Handa R, Falchook AD, Chen RC. Change in

prostate biopsy pathology reading on a second pathology review at an academic medical center. ASTRO 2014. Poster presentation.

a. Also presented at UNC Sheldon Resident Research Symposium (by Miller): 3rd

place prize for oral presentation.

82. Ye F, Waddle MR, Usinger DS, Green RL, Spearman K, Barbosa BD, Godley PA, Chen RC.

Comparison of patient versus physician reporting of comorbidities in localized prostate cancer patients, results from the population-based NC ProCESS cohort. ASTRO 2014. Poster presentation.

25

83. Waddle WR, Ye F, Usinger DS, Green RL, Spearman K, Barbosa BD, Godley PA, Chen RC. Which prostate cancer patients receive multidisciplinary consultation? Findings from the population-based NC ProCESS cohort. ASTRO 2014. Poster presentation.

84. Lian J, Shao Y, Chen RC, Shen D, Wang AZ. Prostate deformation from rectal balloon and

dosimetric effects in prostate brachytherapy. ASTRO 2014. Poster presentation.

85. Caster J, Hendrix LH, Chen RC. Pathologic disease extent in patients with biopsy Gleason 6 prostate cancer and high PSA. ASTRO 2014. Oral presentation.

86. Fuller DB, Wong D, Medbery C, Underhill K, Chen RC. Factors that predict GU, GI and sexual quality

of life (QOL) outcomes 3 years after stereotactic body radiation therapy (SBRT) for early prostate cancer, results from a multi-institutional Phase 2 trial. Int J Radiat Oncol Biol Phys 90(1):S459, 2014. ASTRO 2014. Poster presentation.

87. Stover AM, Irwin DE, Chen RC, Chera BS, Mayer DK, Muss HB, Rosenstein DL, Shea TC, Wood

WA, Lyons JC, Reeve BB. A pilot study implementing real-time, electronic patient-reported data into cancer care: cancer patients’ and clinicians’ perceptions of acceptability and value. Annual meeing of Academy Health, 2014. Poster presentation.

88. Falchook AD, Chen RC. Association between Certificate of Need (CON) Legislation and radiotherapy

use among elderly patients with early cancers: a population-based examination. ASCO Quality Symposium, 2014. Poster presentation.

89. Falchook AD, Martin NE, Chen RC. Stage at presentation and survival outcomes of patients with

Gleason 8-10 prostate cancer and low PSA. The Genitourinary Symposium 2015. Poster presentation. [Resident received ASCO Merit Award]

90. Mak KS, Smith A, Eidelman A, Clayman RH, Cheng JS, Matthews J, Niemierko A, Nielsen ME,

Feldman AS, Lee RJ, Zietman AL, Shipley WU, Chen RC, Milowsky MI, Efstathiou JE. Quality of life in long-term survivors of muscle-invasive bladder cancer. Submitted to The Genitourinary Symposium 2015.

91. Wang EH, Wang SY, Soulos PR, Chen RC, Kim SP, Gross CP, Yu JB. Changes in quality of life after

radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapy. American Radium Society 2015. Oral presentation. [Student received award]

92. Mayer DK, Deal A, Crane J, Chen RC, Asher G, Hanson LC, Wheeler SB, Gerstel A, Rosenstein DL.

Using Survivorship Care Plans (SCP) to Improve Cancer Communication and Care Coordination. ASCO 2015. Poster presentation.

93. Mohiuddin J, Deal A, Carey L, Lund J, Baker BR, Zagar T, Jones E, Marks L, Chen RC. Utilization of

neoadjuvant systemic therapy (NST) for breast cancer. ASCO 2015. Poster presentation.

94. Baker BR, Basak R, Mohiuddin J, Chen RC. Disparity by insurance status and race in receipt of aggressive and advanced treatments for high risk prostate cancer (PCa). ASCO 2015. Poster presentation.

95. Falchook AD, Mohiuddin JJ, Chen RC. Impact of race and insurance status on time to breast cancer

treatment across the US. ASCO 2015. Publication only.

96. Gao Y, Lian J, Chen R, Wang A, Shen D. Fully automatic segmentation of male pelvic organs on CT without manual intervention. AAPM 2015. Oral presentation.

26

97. Mak KS, Smith A, Eidelman A, Clayman RH, Cheng JS, Matthews J, Nimierko A, Nielsen ME, Feldman AS, Lee RJ, Zietman AL, Shipley WU, Chen RC, Milowsky MI, Efstathiou JA. Quality of life in long-term survivors of muscle-invasive bladder cancer. Submitted to ASTRO 2015.

98. Falchook AD, Mohiuddin JJ, Chen RC. Trends in androgen deprivation therapy (ADT) use with

radiation for intermediate- and high-risk prostate cancer across the US. Submitted to ASTRO 2015.

99. Mohiuddin JJ, Deal A, Lund J, Carey L, Baker BR, Zagar T, Jones E, Marks L, Chen RC. Effectiveness of neoadjuvant chemotherapy in reducing mastectomy for women with breast cancer, analysis of a large national database. Submitted to ASTRO 2015.

100. Baker BR, Cosgrove CM, Altekruse S, Mohiuddin JJ, Chen RC. Association between

socioeconomic status (SES) variables and outcomes using registry data – is regional or individual SES more important? Submitted to ASTRO 2015.

101. Holmes JA, Bensen JT, Mohler JL, Michele M, Chen RC. Quality of care received in a population-

based prospective prostate cancer cohort using national consensus indicators. Submitted to ASTRO 2015.

102. Quach CW, Langer MM, Usinger DS, Chen RC, Reeve BB. Reliability and validity of PROMIS

measures administered via telephone interview in a longitudinal, population-based study of men with localized prostate cancer. Submitted to ISOQOL 2015.

103. Langer MM, Reeve BB, Quack CW, Usinger DS, Chen RC. A comparison of effect size measures

for differential item functioning analysis with ordinal logistic regression techniques in a PROMIS anxiety measure. Submitted to ISOQOL 2015.